Full Press Release Details
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. The opening celebration, held on the evening of September 23, attracted a group of over 150 biopharma and CDMO customers. The RTIC buildout, which features product exhibits, purpose-built demonstration areas and technical training space, was designed to provide customers with pre- and post-sales support, and provide a hands-on experience with Repligen’s innovative bioprocessing solutions.
The RTIC enables the functional display of all Repligen bioprocessing technologies; a complete collection from across the company’s global manufacturing sites. Upstream intensification technologies include XCell® ATF and KrosFlo® TFDF® devices and controllers. Downstream products include OPUS® pre-packed chromatography columns, consumables such as Spectrum® hollow fiber filters, TangenX® flat sheet cassettes and devices, and affinity resins. Representing the company’s equipment/consumables integration strategy, there will be a number of systems on permanent display, including KRM™ Chromatography, KrosFlo® RS TFF, KrosFlo® KR2i RPM™, and KrosFlo® FS systems. The CTech™ SoloVPE® and FlowVPX® line of process analytics technologies will also be highlighted. In the area of Fluid Management, products include ProConnex® MixOne carboys systems and flow paths, Metenova magnetic mixers, non-metallic equipment and a number of valve, clamp and tubing technologies.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We’re just thrilled to be opening this Center to elevate the customer experience through live engagement with our subject matter technology experts. The RTIC will demonstrate our end-to-end capabilities, and provide workshops and training grounds for our technical teams and customers. The completion of RTIC represents our unwavering commitment to innovation and sets us up well to meet and exceed customer expectations as we set our sights on 2025 and an expected return to growth on the underpinnings of a strong and expanding biologics market.”
Construction of the RTIC was completed in partnership with the site landlord as part of a broader expansion project over a 20-month period. The RTIC occupies approximately 7,500 square feet of the 55,000 square foot expansion, with the remaining space primarily dedicated to OPUS® warehousing. In total, the Waltham site occupies 182,000 square feet.
In addition to the RTIC opening, the company earlier this year (May) completed a site relocation and expansion in Jüri, Estonia, a milestone in Repligen’s commitment to broadening its presence and enhancing its capabilities in European and global bioprocessing markets. The world-class 80,000 square foot facility is leased to house Repligen’s advanced TFF and chromatography systems and technologies, and to serve as a strategically situated Customer Center of Excellence. Activities at the site include R&D, engineering, manufacturing, sales, service and technical support. The facility is LEED Silver certified and embodies Repligen’s commitment to environmental stewardship and corporate responsibility.
About Repligen Corporation
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.